KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Enterprise Value (2016 - 2026)

Pfizer has reported Enterprise Value over the past 18 years, most recently at -$12.8 billion for Q1 2026.

  • Quarterly Enterprise Value rose 24.95% to -$12.8 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$12.8 billion through Mar 2026, up 24.95% year-over-year, with the annual reading at -$13.3 billion for FY2025, 34.12% up from the prior year.
  • Enterprise Value was -$12.8 billion for Q1 2026 at Pfizer, up from -$13.3 billion in the prior quarter.
  • Over five years, Enterprise Value peaked at -$6.8 billion in Q2 2024 and troughed at -$44.5 billion in Q3 2023.
  • The 5-year median for Enterprise Value is -$17.0 billion (2025), against an average of -$20.9 billion.
  • Year-over-year, Enterprise Value surged 84.67% in 2024 and then crashed 89.48% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$22.5 billion in 2022, then skyrocketed by 44.76% to -$12.4 billion in 2023, then tumbled by 62.56% to -$20.2 billion in 2024, then soared by 34.12% to -$13.3 billion in 2025, then grew by 3.95% to -$12.8 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Enterprise Value are -$12.8 billion (Q1 2026), -$13.3 billion (Q4 2025), and -$14.7 billion (Q3 2025).